1174321-06-2

Basic information

• Product Name: 5-(trifluoroMethyl)pyrazine-2-carboxylic acid
• Synonyms: 5-(trifluoroMethyl)pyrazine-2-carboxylic acid;5-Difluoromethylpyrazine-2-carboxylic acid
• CAS NO: 1174321-06-2
• Molecular Formula: C₆H₄F₂N₂O₂
• Molecular Weight: 174.1049664
• Mol File: 1174321-06-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 319.8±42.0 °C(Predicted)
• Appearance: /
• Density: 1.496±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.59±0.10(Predicted)
• CAS DataBase Reference: 5-(trifluoroMethyl)pyrazine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(trifluoroMethyl)pyrazine-2-carboxylic acid(1174321-06-2)
• EPA Substance Registry System: 5-(trifluoroMethyl)pyrazine-2-carboxylic acid(1174321-06-2)

Safety Data

• Hazardous Substances Data: 1174321-06-2(Hazardous Substances Data)

Usage

General Description

5-(Trifluoromethyl)pyrazine-2-carboxylic acid is a chemical compound with a molecular formula of C6H3F3N2O2. This organic compound belongs to the class of pyrazines, which are polycyclic aromatic compounds containing a pyrazine ring, a six-membered aromatic heterocycle with two nitrogen atoms replacing two nonadjacent carbon atoms. The trifluoromethyl group attached to the pyrazine ring significantly affects the compound's reactivity and properties. This chemical is used in various applications, including as a key intermediate in organic synthesis and in the manufacturing of pharmaceuticals. Its acidic property comes from the presence of the carboxylic acid group in the molecule.

Upstream product

• 36070-80-1 5-chloropyrazinoic acid 
• 1402742-25-9 C₁₃H₁₉N₃O₂ 
• 1174321-08-4 t-butyl 5-formylpyrazine-2-carboxylate 
• 1174321-07-3 t-butyl 5-((E)-2-dimethylamino-vinyl)-pyrazine-2-carboxylate 
• 1151655-02-5 t-butyl 5-methylpyrazine-2-carboxylate 
• 5521-55-1 2-methylpyrazin-5-carboxylic acid 
• 1174321-09-5 t-butyl 5-difluoromethylpyrazine-2-carboxylate 
• 210037-58-4 5-bromopyrazine-2-carboxylic acid methyl ester 
• 33332-25-1 methyl 5-chloropyrazine-2-carboxylate 

Downstream Products

• 1262799-50-7 tert-butyl ((4aS,5S,7aS)-7a-(5-amino-2-fluorophenyl)-3-ethyl-4-oxo-5-(trifluoromethyl)-3,4,4a,5,7,7a-hexahydrofuro[3,4-d]pyrimidin-2-yl)carbamate 
• 1262799-33-6 tert-butyl ((4aS,5R,7aS)-7a-(5-amino-2-fluorophenyl)-3,5-dimethyl-4-oxo-3,4,4a,5,7,7a-hexahydrofuro[3,4-d]pyrimidin-2-yl)(N-tert-butoxycarbonyl)carbamate 
• 1262798-89-9 N-(3-((4aS,5R,7aS)-2-amino-3,5-dimethyl-4-oxo-3,4,4a,5,7,7a-hexahydrofuro[3,4-d]pyrimidin-7a-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide 
• 1262799-45-0 tert-butyl ((4aS,5S_.7aS)-7a-(5-(5-(difluoromethyl)pyrazine-2-carboxamido)-2-fluorophenyl)-3-methyl-4-oxo-5-(trifluoromethyl)-3,4,4a,5,7,7a-hexahydrofuro[3,4-d]pyrimidin-2-yl)carbamate 
• 1262798-95-7 N-(3-((4aS,5S,7aS)-2-amino-3-methyl-4-oxo-5-(trifluoromethyl)-3,4,4a,5,7,7a-hexahydrofuro[3,4-d]pyrimidin-7a-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide 
• 1262803-10-0 N-(3-((4aR,5S,7aS)-2-amino-5-(fluoromethyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]oxazin-7a-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide 
• 1600508-00-6 N-(3-((6S,7R)-9-amino-6-fluoro-7-methyl-5,5-dioxido-5-thia-8-azaspiro[3.5]non-8-en-7-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide 
• 1624605-10-2 N-(3-((4S,6S)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-5-chloro-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide 
• 1624604-92-7 N-(3-((4S,6S)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4,5-difluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide 
• 1388651-30-6 N-(3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide 

Relevant articles and documents

Synthesis of BACE1 Inhibitors E2609 / E2071 via Oxime-Olefin Cycloaddition following a Process Risk Mitigation Strategy

Process development of E2609 from the preclinical stage to the clinical stage following a process risk mitigation strategy is described here. Key features include a turbo Grignard reaction monitored by in-situ IR, [3 + 2] cycloaddition in water, chemoselective amide coupling via in-situ protection, and a Reformatsky/decarboxylation approach to install a difluoromethyl group. Toward safe and scalable manufacture of E2071, an analog of E2609, a flow-reaction process for trifluoromethylation of aldehydes is presented here.

C5-C6 OXACYCLIC-FUSED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE

In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula : (I) and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein each of ring A, ring B, ring C, R2, R3, R4, m, n, p, and -L1- is as defined herein. The novel compounds of the invention may be useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including Alzheimer's disease, are also disclosed.

FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS

The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or -C≡N; and pharmaceutically acceptable salts thereof; which compound has an Αβ production inhibitory effect or a BACEl inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Αβ and typified by Alzheimer-type dementia.